Dr. Jiangbing Zhou is an Assistant Professor of Neurosurgery and Biomedical Engineering. His research centers on developing translational nanomedicine and stem cell therapy for treatment of neurological disorders, including brain cancer and neurodegenerative diseases, through a unique combination of neuroscience, stem cell biology, and emerging nanotechnology. The ultimate goal of Zhou lab research is to combine these advances to establish more effective methods to treat neurological disorders.
Education & Training
B.S. East China University of Science and Technology (1998)
M.S. Tsinghua University (2001)
Ph.D. Johns Hopkins University (2008)
Postdoctoral Fellow Yale University, Department of Biomedical Engineering
Honors & Recognition
B*CURED Foundation Clinical Research Investigator Award, 2011
Glioblastoma multiforme (GBM) is highly resistant to surgical, pharmacological, and radiation therapies and poses an important public health problem in the US. Recent studies suggest that one of the reasons for failure results from inability to target the most treatment-resistant cell population in the tumor called brain cancer stem cells (BCSCs). Accumulated evidence indicates that BCSCs are the origin of glioma development, as they have the exclusive ability to drive tumor formation and a high capacity to promote angiogenesis. Unfortunately, standard regimens for treating gliomas are not able to effectively eliminate BCSCs.
Clearly, improved treatment of malignant gliomas requires effective treatment of BCSCs. However, eradicating BCSCs is a major challenge. Apart from the unavailability of BCSC-specific therapeutic agents, conventional drug delivery approaches do not effectively reach this target population, because the brain possessesthe blood brain barrier (BBB).
To address these challenges, we develop a multidisciplinary research program that combines recent advances in brain cancer stem cell biology, neural stem cell biology, and emerging nanotechnology. Specifically, we take an integrative systems biology approach to identify novel therapeutic targets for brain cancer. At the same time, we develop multifunctional nanoparticles and engineered stem cells for delivering therapeutic agents or gene therapy to the brain. We expect that the combination of these advances will lead to more effective methods to treat human brain cancer.
- Zhou J, Patel T, Fu M, Piepmeier JM, Saltzman WM, Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors, Biomaterials, 2012;33(2):583-91
- Zhou J, Garth S, Himes B, Kofi-Buaku A, Saltzman WM, Novel Delivery Strategies for Glioblastoma, The Cancer Journal, 2012;18(1):89-99.
- Patel T, Zhou J, Piepmeier JM, Saltzman WM, Polymeric Nanoparticles for Drug Delivery to the Central Nervous System, Advanced Drug Delivery Reviews, 2012, 64(7):701-5
- Zhou J, Liu J, Jiang Z, Patel T, Weller C, Piepmeier JM, Saltzman WM, Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery, Nature Materials, 2011, 11(1):82-90
- Zhou J, Zhang H, Gu P, Bai J, Yin D, and Zhang Y, Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Research Treatment, 2009, 115:269-77
- Zhou J, Zhang Y, Preclinical development and screen of cancer stem cell targeted drugs. Expert Opinion in Drug Discovery, 2009; 4(7):741-52
- Zhou J, Zhang H, Gu P, Margolick JB, Zhang Y, Identification of NF- B pathway inhibitors preferentially inhibit breast cancer stem cells. Breast Cancer Research Treatment, 2008;111(3):419-27
- Zhou J, Zhang Y, Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle, 2008; 7(10):1360-70
- Tao SC*, Li Y*, Zhou J*, Qian J, Schnaar RL, Goldstein IJ, Zhang Y, Zhu H, Schneck JP, Use of mammalian cell surface glycan signatures in pathogen tropism, cell differentiation, and biomarker identification. (*equal contribution) Glycobiology, 2008; 18(10):761-69
- Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Margolick JB, Liotta LA, Petricoin III E, and ZhangY. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A, (direct submission) 2007, 41(104):16158-63
- Zhou J, Wang Z, Sun SQ, Zhang HJ, A rapid method for detecting conformational changes of differentiation and apoptosis HL60 cells by Fourier Transform Infrared Spectroscopy. Biotechnology and Applied Biochemistry, 2001; 33:127-32
Assistant Professor of Neurosurgery and of Biomedical Engineering